There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Cocrystal Pharma (COCP – Research Report) and Lantern Pharma (LTRN – Research Report) with bullish sentiments.
Cocrystal Pharma (COCP)
In a report released today, Robert LeBoyer from Noble Financial reiterated a Buy rating on Cocrystal Pharma, with a price target of $5.00. The company’s shares closed last Monday at $0.55, close to its 52-week low of $0.47.
According to TipRanks.com, LeBoyer is a 4-star analyst with an average return of
Cocrystal Pharma has an analyst consensus of Moderate Buy, with a price target consensus of $4.50, implying a 675.9% upside from current levels. In a report issued on January 31, H.C. Wainwright also reiterated a Buy rating on the stock with a $4.00 price target.
Lantern Pharma (LTRN)
In a report released today, Kyle Bauser from Colliers Securities reiterated a Buy rating on Lantern Pharma, with a price target of $29.00. The company’s shares closed last Monday at $6.78, close to its 52-week low of $5.45.
According to TipRanks.com, Bauser is a 1-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Lantern Pharma with a $29.00 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on COCP:
- Analysts Offer Insights on Technology Companies: Fiserv (FISV) and Twilio (TWLO)
- Eagle Bulk Shipping (EGLE) Receives a Buy from Noble Financial
- Mizuho Securities Keeps Their Hold Rating on Incyte (INCY)
- Deutsche Bank Sticks to Their Hold Rating for M&G Plc (MGPUF)
- J.P. Morgan Reaffirms Their Hold Rating on Clarkson (CKNHF)